AnaptysBio, Inc. (ANAB) vs Braveheart Bio, Inc. (BRVE)

A side-by-side comparison of AnaptysBio, Inc. and Braveheart Bio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ANAB

AnaptysBio, Inc.

$1.46B

$49.41HealthcareDelayed quote: Oct 6, 2026, 9:30 AM EDT

BRVE

Braveheart Bio, Inc.

$1.53B

$21.59HealthcareDelayed quote: Oct 6, 2026, 9:30 AM EDT

Total return — ANAB vs BRVE

growth of $100 · dividends reinvested · last 1y

ANAB -8.3% (-8.3%/yr)BRVE +18.6% (+18.6%/yr)BRVE compounded faster over this window

ANAB BRVE

Metrics side by side

Total return (annualized)

Metric	ANAB	BRVE
Total return (1Y)	137.50%	N/A
Total return CAGR (3Y)	55.19%	N/A
Total return CAGR (5Y)	21.54%	N/A

BRVE is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Go deeper

Full ANAB analysis Full BRVE analysis Interactive comparison tool

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.